Key result
Higher baseline Respiratory Sinus Arrhythmia (RSA) significantly predicted positive clinical response to 12 weeks of antidepressant treatment in patients with Major Depressive Disorder.
Why the study?
Do baseline heart rate variability components (RSA and LF-HRV) predict treatment response to escitalopram or quetiapine in patients with Major Depressive Disorder?
Population
66 enrolled patients with Major Depressive Disorder, males and females 20-65 years of age meeting DSM-IV…
Comparison
Escitalopram or Quetiapine fumarate ER over 12… vs Healthy controls and treatment non-responders.
Design
Cohort
Follow-up
12 weeks
Authors
Loading...
Baseline RSA was associated with antidepressant response in MDD; leaves open its role as a treatment-selection biomarker pending randomized validation.
Cohort (n=77)
No
Do baseline heart rate variability components (RSA and LF-HRV) predict treatment response to escitalopram or quetiapine in patients with Major Depressive Disorder?
Standardized Mean Difference: 1.26
Absolute Event Rate: 6.18% vs 4.78%
p-value: p=<0.005
Baseline heart rate variability components (RSA and LF-HRV) may serve as predictive biomarkers for antidepressant treatment response in patients with Major Depressive Disorder.
Hage et al. (2017) conducted a cohort in Major Depressive Disorder (n=77). Baseline Respiratory Sinus Arrhythmia (RSA) vs. Treatment non-responders was evaluated on Baseline Respiratory Sinus Arrhythmia (lnRSA) in treatment responders vs non-responders (Cohen's d 1.26, p=<0.005). Higher baseline Respiratory Sinus Arrhythmia (RSA) significantly predicted positive clinical response to 12 weeks of antidepressant treatment in patients with Major Depressive Disorder.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: